Key clinical point: Chlorotoxin (CLTX)-directed chimeric antigen receptor (CAR) T cells have proved active against glioblastoma tumor cells with minimal off-target effects.
Major finding: Intracranial administration of CLTX-CAR T cells controlled tumor growth and extended survival in mouse models of glioblastoma.
Study details: A preclinical study of CLTX-directed CAR T cells.
Disclosures: The study was funded by the Ben and Catherine Ivy Foundation and the National Institutes of Health. Two authors reported financial affiliations with Mustang Bio.
Wang D et al. Sci Transl Med. 2020 Mar 4. doi: 10.1126/scitranslmed.aaw2672.